The Latest in Multiple Sclerosis Hub

Reanalysis of Cladribine Data Confirms and Extends the Benefits Seen in ORACLE-MS

May 26, 2016

Multiple Sclerosis

Does Natalizumab Benefit Patients With Secondary Progressive MS?

May 26, 2016

Multiple Sclerosis

Age, lower baseline ALC increase dimethyl fumarate lymphopenia risk

May 26, 2016

Multiple Sclerosis

Ocrelizumab bests interferon for relapsing MS at 2 years

May 25, 2016

Multiple Sclerosis

Screen and treat MS patients for emotional distress, depression

May 17, 2016

Multiple Sclerosis

Data support safety of MS drugs before, during early pregnancy

May 15, 2016

Multiple Sclerosis

Evidence Builds for Mesenchymal Stem Cell Therapy in Multiple Sclerosis

May 3, 2016

Multiple Sclerosis

Fewer new lesions, side effects differentiate fingolimod from dimethyl fumarate

April 28, 2016

Multiple Sclerosis

Clemastine Fumarate May Repair Myelin in People With MS

April 25, 2016

Multiple Sclerosis

New data help guide the stopping of disease-modifying drugs in MS

April 19, 2016

Multiple Sclerosis

Rituximab bests fingolimod in MS patients switching from natalizumab

April 4, 2016

Multiple Sclerosis

ORATORIO Subgroup Analysis Looks at Baseline Enhancement Activity’s Effect on Outcome

March 23, 2016

Multiple Sclerosis

High Coffee Consumption May Decrease Risk for MS

March 22, 2016

Multiple Sclerosis

Drugs for Progressive MS Could Target Multiple Disease Mechanisms

March 22, 2016

Multiple Sclerosis

Evidence builds for mesenchymal stem cell therapy in MS

March 7, 2016

Multiple Sclerosis